In-house efforts to boost vaccines

As a silent but necessary partner, adjuvants can't be ignored by biotech vaccine developers who have to choose among competing candidates to provide the immune stimulant required to make the vaccines work.

Adjuvant developers Cambridge Biotech Corp. (CBCX), CytRx Corp. (CYTR) and Ribi ImmunoChem Research Inc. (RIBI) are adding proprietary products to the short list of non-proprietary compounds, which they hope become the adjuvants of choice for as many vaccines as possible. ...